ANZCTR search results

Fibrotic tissue may cause myocardial dysfunction and failure. So it’s important to establish a non invasive method to assess myocardial fibrosis. Cardiac MR relaxometry can quantify myocardial fibrosis using tagging, T2 star quantification, T1 mapping, first pass perfusion and delayed enhancement techniques. These results will correlate with the echocardiography methodology and myocardial biopsy findings. the aims of this study to determine a MRI relaxometry of normal myocardium and any Alteration of relaxation times for early fibrosis in hypertensive disease. also, To detect possible fibrosis of remote myocardium in patients with prior infarction by analysis of delayed enhancement images after injection of MRI contrast agent. The hypothesis of this study is that Magnetic Resonance relaxometry can assess and measure early diffuse fibrosis in hypertensive heart disease. the expected benefits from this study is Understanding the Tost effective clinical treatments will lead to improved health outcomes at lower cost. also, Early intervention is known to reduce the cost burden to the community and healthcare delivery system. in addition, Validation of non invasive methods of measuring early fibrotic changes in myocardium is essential to direct the clinical decision making

177Lu-Octreotate is synthesized from [DOTA,Tyr3]Octreotate labelled with 177LuCl3 (7.8 GBq) distributed by IBD (Baarle-Nassau, the Netherlands). Each patient receives an infusion of aminoacids (Baxter Synthamin) containing 11.6g lysine and 23g arginine/L at 250 ml/hr. Thirty minutes later the radiolabelled somatostatin analogue is co-infused via a side-line over 10-20 minutes. Routine antiemetic therapy is given in the form of Tropisetron (5mg) intravenous (IV) bolus and oral Lorazepam (2mg). The chemotherapy with oral Capecitabine 1650mg/m2 will be reduced to 1500mg/m2 (in line with the American Society of Clinical Oncology (ASCO) dosage), for 14 consecutive days, and commenced on the morning of radionuclide therapy. Cycles will repeated each 8 weeks at the time of each subsequent radionuclide infusion. Temozolomide will be introduced on a dose escalation schedule, in cohorts of 3 patients, commencing at 100mg/m2 for 5 days. A standard dose escalation trial design will be followed with 3 patients completing 2 cycles at the starting dose (100mg/m2) prior to escalation to 150mg/m2 in the next 3 patient cohort. The ultimate maximum dose will not exceed the 200mg/m2 safe level established in the ASCO protocol. In the absence of toxicity all subsequent patients will be treated at this level All of the previously monitoring, including weekly blood testing and 2 monthly scanning, will remain unchanged from the original CLEMENT protocol. Assessments: Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) will be performed at baseline and then at each new treatment cycle (8 weeks). Quantitative uptake of 177Lu-octreotate in the tumours will be measured by serial whole body imaging at 4, 24, 48 hours and 5 days and graded according to a 4 point visual scale.

This project primarily aims to investigate the efficacy of a physiotherapy program to treat hip joint osteoarthritis. Secondary aims are to assess changes in relevant musculoskeletal impairments with treatment, maintenance of treatment effects over 6 months and the cost-effectiveness of physiotherapy. Primary hypothesis: A 12-week multimodal physiotherapy program will result in significantly greater improvements in pain and physical function than sham physiotherapy immediately post-treatment in individuals with hip OA.

Hyperphosphatemia (high phosphate concentration in the blood) is common in dialysis patients. Hyperphosphatemia can cause renal bone disease and is also associated with higher mortality. Most dialysis patients are prescribed phosphate binder drugs to bind phosphate in the gut and prevent its absorption. These include Calcium Carbonate (Caltrate (Registered Trademark) or Calsup (Registered Trademark)), Aluminium Hydroxide (Alu-Tab (Registered Trademark)), Lanthanum Carbonate (Fosrenol (Registered Trademark)) and Sevelamer (Renagel (Registered Trademark)). In theory some phosphate binder drugs need the stomach to be acidic to work effectively and bind phosphate. Haemodialysis patients are often prescribed gastric acid suppressant drugs to treat gastric ulcers and gastric reflux disease (heartburn). These drugs include Pantoprazole (Somac (Registered Trademark)), Omeprazole (Losec (Registered Trademark)) and Esomperazole (Nexium (Registered Trademark)). These acid suppressing drugs may reduce stomach acidity and therefore the effectiveness of phosphate binders. This potential drug interaction may worsen hyperphosphatemia The primary purpose of this study to evaluate the effectiveness of phosphate binders in managing hyperphosphataemia when they are co-administered with acid suppressive therapy in haemodialysis patients

The study investigated the effectiveness of a high calorie, high protein nutritional supplement in terms of changes in recovery rate as measured by abilities in activities of daily living (ADL), and nutritional status.

Background Proponents of minimally invasive knee replacements argue that retracting rather than everting the patella results in quicker postoperative recovery and improved function compared to the standard approach. We aimed to investigate this in a group of patients undergoing knee arthroplasty using a standard medial parapatellar approach. Methods In a prospective randomized double-blinded study sixty-six patients undergoing total knee arthroplasty through a standard medial parapatellar approach were assigned to either retraction or eversion of the patella. An independent observer assessed the Oxford knee score, the SF12 score, visual analog pain scores and range of motion data preoperatively, at three months and at one-year post surgery. Results Early (3 month) follow-up showed no difference in Oxford knee scores, SF12, visual analog pain scores or flexion. A statistically significant improvement in extension was found in the retraction group but this was not thought to be clinically significant. There was no difference in any outcomes at one year. There were two partial divisions of the patella tendon in the retraction group, but no patella related complications in the eversion group Conclusions Retracting rather than everting the patella during total knee arthroplasty results in no significant clinical benefit. There is an increased risk of damage to the patellar tendon, and reduced visualization of the lateral compartment.

Atomoxetine is an established treatment for ADHD. Despite its routine use, little is understood how it influences brain functioning. This study will test the effect of atomoxetine treatment on a range of brain functions relevant to ADHD.

At present, about 50% of homosexual men have HIV tests at least once per year. Increasing this proportion is predicted to reduce the rate of HIV transmission in the population, due to changes in sexual behaviour brought about by diagnosis. Rapid HIV tests are not currently approved or available for general use in Australia, but these may prove more accepatable because patients do not need to return for a second consultation for their result and a less invasive sample is required. This study is a randomised trial of the effect of making rapid HIV tests available to men having sex with men (MSM) on the frequency with which they have HIV tests. Consenting HIV-negative MSM requesting an HIV test at Melbourne Sexual Health Centre (MSHC) will be randomised in equal proportion to either onging access to a rapid test for 18 months or to standard laboratory-based serology (which requires them to return for their result in a week). This is not blinded; both groups are sent three-monthly reminders by e-mail and SMS, reminding them of their study allocation, and asking them to complete six-monthly questionnaires on sexual behaviour and whether they have had HIV tests elsewhere.

The hypothesis to be tested by this study is that the improved clearance of middle molecules (thought to be important uremic toxins) by the new FX 80 membrane would lead to less oxidative stress and inflammation when compared to dialysis using a standard hig-flux membrane.